Lung Cancer Research Awards

Research Awards

Adequate research funding is key to furthering developments in lung cancer treatment. Through partnering with foundations, non-profits, corporations and individual donors, the International Lung Cancer Foundation provides funding opportunities each year to facilitate advances and save lives.

International Lung Cancer Foundation Research Awards

Each year, the International Lung Cancer Foundation provides research funding for young and early-career investigators.

This funding recognizes scientific excellence and encourages innovation in the fields of lung cancer prevention and translational medicine worldwide.

Our next Research Awards cycle begins on Monday, June 15. Check out our application site for details on the available awards and how to apply.

APPLY for ILCF Awards NOW

Lung Ambition Alliance Junior Faculty Research Grants for the Study of Lung Cancer and COVID-19

Currently, quality data are scarce concerning COVID-19 positive lung cancer patients. COVID-19, or other respiratory coronavirus infections, will likely continue for the foreseeable future and there needs to be a better understanding of how this virus affects lung cancer patients, lung cancer treatment and therapies, and the overall effects on treatment outcomes. The International Lung Cancer Foundation is pleased to join forces with the Lung Ambition Alliance on a new program to fund ground-breaking research related to patients with lung cancer and COVID-19. Collaborative, multidisciplinary applications are encouraged.

APPLY for LAA Grants NOW

2020 Fellowship Award Winners

Biagio Ricciuti | Dana-Farber Cancer Institute

Project Title: Impact of DNA Damage Repair (DDR) Gene Mutations on Efficacy of PD-L1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer (NSCLC)

Wencai Zhang | University of Central Florida

Project Title: MicroRNA-Mediated Precancerous Metabolism Accelerates Progression of Atypical Adenomatous Hyperplasia of the Lung

Triparna Sen | Memorial Sloan Kettering Cancer Center

Project Title: Targeting Epigenetic Modifiers to Reactivate Anti-tumor Immune Response in Small Cell Lung Cancer

Cleo Goyvaerts | Vrije Universiteit Brussels

Project Title: Creation of a 3D CRiMe Scene to Unravel Cytotoxic T-Cell Resistant Mechanisms

Hua Zhang | New York University School of Medicine

Project Title: Targeting CDK7 to Enhance Immunotherapy in Small Cell Lung Cancer

Kasey Cargill | UT MD Anderson Cancer Center

Project Title: Elucidating the Metabolic Profiles and Vulnerabilities to Metabolic Inhibitors Among Small Cell Lung Cancer Subtypes

Karmele Valencia | University of Navarra

Project Title: Dual Serine/Threonine and Tyrosine Kinase (DSTYK) as a New Target for Lung Cancer Therapy and Immunotherapy Combination

Jon Zugazagoitia

Project Title: Resistance to PD-1 Checkpoint Blockade in NSCLC Induced by Tumor Cell CD127 (IL-7R) Expression: Validation, Functional Assessment and Targeted Therapeutic Strategies

2019 Fellowship Award Winners

HYPERBOLIC: HYPER-progression Biological Outlines in advanced Lung cancer upon Immune Checkpoints blockade

Dr. Roberto Ferrara

I.R.C.C.S. National Cancer Institute, Milan, Italy

Evaluating LAG3 on tumor-specific CD8+ T cells as a blood-based biomarker in NSCLC patients receiving anti-PD1 therapy

Dr. Ashwin Somasundaram

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Cancer Survivors Experiencing Cancer Related Fatigue: A Phase 2 Study Evaluating A Combined Physical Activity (Pa) and Mindfulness Based Stress Reduction (Mbsr) Program: The Zenergise Trial

Dr. Ashanya Malalasekera

Concord Cancer Centre, Sydney, Austrialia

Evaluating LAG3 on tumor-specific CD8+ T cells as a blood-based biomarker in NSCLC patients receiving anti-PD1 therapy

Dr. Tejas Patil

University of Colorado Denver, Denver, Colorado, USA

Towards a Better Therapeutic Ratio: The Role of Magnetic Resonance-Linear Accelerator (MR-Linac)
in High-Risk Early-Stage Lung Cancer

Dr. Chen Hanbo

VU University Medical Center Amsterdam, Amsterdam, Netherlands

FN14 Targeted Nanoparticles, A New Target and Treatment for Mesothelioma.

Dr. Warren Naselsky

University of Maryland Medical Center Baltimore, Maryland, USA

Exploiting a novel prognostic biomarker and therapeutic target to enhance chemotherapy response in non-small cell lung cancer patients.

Dr. Mark Adams

Translational Research Institute, Queensland University of Technology, Woolloongabba, Australia

2018 Fellowship Award Winners

The IASLC award has been greatly impactful in my career for a number of reasons. It allows me to learn how to use innovative and powerful technology. I chose a career in lung cancer research because lung cancer is the leading cause of cancer related deaths, a significant burden for hundreds of thousands of people and their families and because I believe that the scientific community is in the brink of major advances in the field.

Dr. Anastasios Dimou

University of Colorado, Anschutz Medical Campus in Aurora, CO

The support of the IASLC has allowed me to pursue an ambitious genome sequencing project that I wouldn’t be able to fund via typical grant mechanisms at this time in my career. It is allowing our lab to launch a unique collaboration with the Women’s Health Initiative to better understand the genomic features of lung cancer in women who have never smoked.

Dr. Alice Berger

Ph.D., Assistant Professor of Human Biology, Fred Hutchinson Cancer Research Center

By receiving the FMFLC/IASLC fellowship, not only was I able to make my know-how available to my colleagues and the scientific community at UCLA, but most importantly I started to connect to other scientists within my group and outside, who helped me optimize and further develop techniques, which are now state of the art in the field of molecular and cancer biology and the translational aspect of it.

Dr. Eva Koziolek

Assistant Project Scientist, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles

The IASLC Young Investigator Award had clearly enhanced my academic career. To be the recipient of this prestigious international award has opened new doors and opportunities for me. The funding this award provided for my new scientific laboratory has been particularly helpful during my start-up phase, where it has allowed a research project on developing new treatments for SCLC to be properly resourced and to proceed ahead without hindrance.

Dr. Benjamin Lok

MD, FRCPC/Clinician-Scientist, Assistant Professor, Princess Margaret Cancer Centre

PAST ILCF FELLOWS

FELLOWS: 2000-2018

Annual ILCF Funding Opportunities

Spring Funding Opportunities

Lung Cancer Foundation of America- Bristol-Myers Squibb/IASLC Foundation Young Investigator Research Awards in Translational Immuno-oncology
The objective of the LCFA-BMC/IASLCF Young Investigator Research Awards is to support research in translational immune-oncology by early career investigators that aim to improve the care of individuals with lung cancer and to reduce the burden of these diseases. Four awards available/ $200,000 for two years.

Free ME from Lung Cancer (FMFLC) and the IASLC Foundation Joint Fellowship Award
The FMFLC-IASLC award is designed to fund research that will deliver a meaningful and measurable result for the early detection of lung cancer and that has a high probability of near-term benefit to lung cancer patients or individuals at risk. One award available/ $200,000 for two years.

Fall Funding Opportunities

John’s Legacy Fellowship
The objective of the new IASLCF John’s Legacy Fellowship Award is to encourage that the early detection and screening of lung cancer become a standard of care in annual physicals. The fellowship was conceived by IASLCF board member, Lauren Fisher, in memory of her late husband, John Fisher. One award available/ $50,000 for one year.

IASLC Foundation Fellowship and Young Investigator Awards Funding for IASLC Foundation Fellowship and Young Investigator Awards provides for the training of research fellows and young investigators who wish to pursue a career in lung cancer diagnosis, treatment, or laboratory research as well as other aspects of the study of lung tumors. Six awards available/ $50,000 for one year.

Boehringer Ingelheim IASLC Foundation Chinese Research Fellowship Award
Boehringer Ingelheim, in collaboration with the IASLC, have created the Chinese Lung Cancer Fellowship Award to enable a fellow to come to the United States for a one-year research project. The goal of this fellowship is to reward scientific excellence and to encourage innovative and collaborative investigation in the fields of lung cancer prevention, diagnosis and translational research with a potential impact on the management of lung cancer. One award available/ $40,000 for one year.

Prevent Cancer Foundation and the IASLC Foundation Joint Research Grant
The goal of this Prevent Cancer Foundation/IASLC Foundation joint grant is to reward scientific excellence and to encourage innovative investigations in the field of lung cancer prevention research and translational research with a potential impact on the management of lung cancer. One award available/ $250,000 for one year.

Partners_Graphic_NS.2